CAS: 53427-97-7; 1-(4-Nitrophenyl)Pyridin-2(1H)-One

上下游产品

potassium 2-oxo-2H-pyridin-1-ide 4-chlorobenzonitrile 2-hydroxypyridin p-nitrobenzene iodide 1-(p-Nitrophenyl)-2-thiopyridon 1-(4-nitrophenyl)-3,5-dinitro-2-pyridone N-(4-nitrophenyl)cyclohexylamine 1-(4-aminophenyl)pyridin-2(1H)-one

📜2-羟基吡啶,对氟硝基苯置于potassium Carbonate体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应生成 1-(4-硝基苯)-1H-吡啶-2-酮
参考文献:作为新型 Fxa 抑制剂的吡咯并 [3,2-D] 嘧啶酮衍生物的合成
标题:作为新型 Fxa 抑制剂的吡咯并 [3,2-D] 嘧啶酮衍生物的合成
摘要:已设计并合成了一系列吡咯并[3,2-D]嘧啶酮化合物作为新型 Fxa 抑制剂.受试化合物的生物测定显示出中等至极好的体外抗凝血效力.进一步在大鼠,Fecl 3诱导的静脉血栓形成模型中评估fxa抑制和生物活性,表明化合物17A具有非常好的fxa抑制活性(ic 50 = 1.57 Nm)和体内抗血栓效力.化合物17A的抗凝血作用在体外或体内均呈剂量依赖性. 结果进一步证实了我们的假设,即大共轭结构是理想的骨架结合 Fxa.
DOI:10.1016/j.Bmcl.2023.129127

专利信息

专利号:US-2006069260-A1
优先权日:2004-09-28
标 题:Preparation of N-aryl pyridones
发明人：ZHANG HUIPING; CHEN BANG-CHI; ZHAO RULIN
权利人:ZHANG HUIPING; CHEN BANG-CHI; ZHAO RULIN
摘要:A novel process and intermediates thereof for making N-aryl pyridones of the type shown below from appropriate pyridinolates is described. n nThese compounds are useful as intermediates for the synthesis of clinical candidates.

专利号:US-2008025986-A1
优先权日:2003-06-06
标 题 :Methods of Treating Tnf-Mediated Disorders
发明人：OZES OSMAN N; BLATT LAWRENCE M
权利人:OZES OSMAN N; BLATT LAWRENCE M
摘要:The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of pirfenidone. The present invention further provides methods of treating end-stage or advanced Type II diabetes, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone and insulin.

专利号:US-3839346-A
优先权日:1972-12-18
标 题:N-substituted pyridone and general method for preparing pyridones
发明人：GADEKAR S
权利人:AFFILIATED MED RES
摘要:1. A PROCESS FOR THE SYNTHESIS OF PYRIDONES OF THE FORMULA 1-A,2-(O=),3-R3,4-R4,5-R5,6-R6-1,2-DIHYDROPYRIDINE WHEREIN A IS AN AROMATIC RADICAL SELECTED FROM THE GROUP CONSISTING OF PHENYL, TOLYL, CHLOROPHENYL, TRIFLUOROMETHYLPHENYL, NAPHTHYL, PYRIDYL, FURYL, THIENYL, THIAZOLYL, PYRIMIDYL, QUINOLYL, IMIDAZOLYL; UP TO TWO OF THE TERMS R3, R4, R5 AND R6 ARE INDIVIDUALLY EACH HYDROGEN OR ALKYL UP TO 6 CARBON ATOMS, ARYL OR SUBSTITUTED ARYL RADICALS WHICH CONSISTS ESSENTIALLY OF THE STEPS OF REACTING A PYRIDONE OF THE FORMULA 2-(O=),3-R3,4-R4,5-R5,6-R6-1,2-DIHYDROPYRIDINE, OR ITS TAUTOMER, 2-(HO-),3-R3,4-R4,5-R5,6-R6-PYRIDINE IN WHICH R3, R4, R5 AND R6 ARE SET FORTH ABOVE, WITH A HALOGENATED COMPOUND OF THE FORMULA AX, WHEREIN X IS EITHER CHLORINE, BROMINE OR IODINE, AT TEMPERATURES RANGING BETWEEN THE MELTING POINT AND BOILING POINT OF SAID HALOGENATED COMPOUND, IN THE PRESENCE OF AN ALKALI METAL CARBONATE AND FINELY DIVIDED METALLIC COPPER.

专利号:US-6300349-B1
优先权日:1995-09-19
标题:Inhibition of tumor necrosis factor alpha
发明人：MARGOLIN SOLOMON B
摘要:In a preferred embodiment, a method for the inhibition of the synthesis and release of tumor necrosis factor from various cells, comprising: administering to a human or other mammal an effective dose of one or more pharmaceutical substances selected from the group consisting of N-substituted 2(1H) pyridones, N-substituted 3(1H) pyridones, and pharmaceutically acceptable salts thereof.

专利号:EP-0866656-B1
优先权日:1995-09-19
标题:Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors
发明人：MARGOLIN SOLOMON B
权利人:MARGOLIN SOLOMON B
摘要:In a preferred embodiment, a method for the inhibition of the synthesis and release of tumor necrosis factor from various cells, comprising: administering to a human or other mammal an effective dose of one or more pharmaceutical substances selected from the group consisting of N-substituted 2(1H) pyridones, N-substituted 3(1H) pyridones, and pharmaceutically acceptable salts thereof.